Azothbio Inc. and Daegu-Gyeongbuk Medical Innovation Foundation have described non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, cancer, endocrine, inflammatory and neurological disorders.
The University of Michigan has synthesized proteolysis targeting chimeras (PROTACs) comprising a von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to a signal transducer and activator of transcription 3 (STAT3)-targeting moiety via a linker.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease, frontotemporal dementia, multiple sclerosis, Nasu-Hakola disease, Parkinson’s disease, rheumatoid arthritis and stroke.
Northeastern University has disclosed cannabinoid CB1 receptor allosteric modulators and monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of pain, inflammation, anxiety, psychosis, traumatic brain injury, post-traumatic stress disorder, epilepsy and neurodegenerative diseases.
Gemvax & Kael Co. Ltd. has identified peptides reported to be useful for the treatment of age-related macular degeneration (AMD), cerebral amyloid angiopathy and Alzheimer’s disease.
Nanjing Reju Therapeutics Inc. has described tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) inhibitors reported to be useful for the treatment of inflammatory-related disorders and cell necrosis-related apoptosis diseases.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Universitat de Barcelona has identified histone-lysine N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors reported to be useful for the treatment of Alzheimer’s disease among others.
RSS